NCT03385226 - A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 15, 2019

Primary Completion Date

September 1, 2023

Study Completion Date

September 30, 2025

Conditions

Cutaneous T Cell LymphomaMycosis Fungoides/Sezary Syndrome

Interventions

DRUG

Pembrolizumab

Pembrolizumab is a humanised monoclonal antibody which targets the programmed cell death 1 (PD-1) receptor. It blocks a protective mechanism on cancer cells, and allows the immune system to destroy those cancer cells.

RADIATION

Radiotherapy

12Gy in 3 fractions

Trial Locations (11)

Unknown

University Hospital Birmingham, Birmingham

Velindre Cancer Centre, Cardiff

University Hospital Coventry, Coventry

Beatson West of Scotland Cancer Centre, Glasgow

Guy's & St Thomas', London

The Christie, Manchester

Clatterbridge Cancer Centre, Metropolitan Borough of Wirral

Freeman Hospital, Newcastle

Nottingham City Hospital, Nottingham

Churchill Hospital, Oxford

Southampton University Hospital, Southampton

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University College, London

OTHER